Advancing Care Coordination, Equity and AI Integration | Predictions for 2025
A prediction for 2025 from Laura Kohlhagen, M.D., MBA, chief medical officer, of Altera Digital Health.
Looking toward 2025, we will see improved care coordination and member engagement as more payers align to trust frameworks and standards like Trusted Exchange Framework and Common Agreement [TEFCA] and Fast Healthcare Interoperability Resources [FHIR].
Kohlhagen
Additionally, more healthcare organizations will leverage AI [artificial intelligence] to identify at-risk patients and proactively provide recommendations for treatment and aid based on social determinants of health. Healthcare organizations placing greater emphasis on health equity will expand initiatives like vaccination campaigns and preventive care programs to better meet the needs of high-risk populations.
Finally, as AI expands across the industry, we will also see increased adoption of AI in claims processing and fraud detection to reduce manual intervention and errors.
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
Is Journavx a Step Forward In Pain Management or a Repeat of Past Mistakes?
March 25th 2025In a Q&A with Josef Witt-Doerring, M.D., former FDA medical officer in the division of psychiatry and the founder and CEO of TaperClinic, he shares the potential benefits and risks of the alternative non-opioid pain medication, expressing that while it could help cut down on opioid use, its long-term impact is unclear.
Read More
Phase 3 Trials of Oral Povorcitinib Show Positive Results in Hidradenitis Suppurativa
March 24th 2025A new drug application for povorcitinib is expected to be filed in late 2025 to early 2026 to treat adult patients with moderate to severe hidradenitis suppurativa, a chronic and painful inflammatory skin condition.
Read More
